Safety and efficacy of zetomipzomib in relapsed or insufficiently responding autoimmune hepatitis: Results from the randomized, double-blind, placebo-controlled, phase 2a PORTOLA study and open-label extension

Craig S. Lammert, Ethan M. Weinberg, Seth N. Sclair, Robert J. Fontana, Neel K. Anand, Janet L. Anderl, David Bade, Shraddha Desai, Christopher J. Kirk, Diana Lam, Eric Lowe, Tony Muchamuel, Kiruthi Palaniswamy, Rachel Peterson, Kathryn Ray, Zung To, Brian B. Tuch, Jennifer A. Whang, Aparna Goel, Unknown

Open source

DOI: 10.1097/hep.0000000000001840
Published: 2026-08-26
Container: Hepatology
Publisher: Ovid Technologies (Wolters Kluwer Health)
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1097/hep.0000000000001840,
  title = {Safety and efficacy of zetomipzomib in relapsed or insufficiently responding autoimmune hepatitis: Results from the randomized, double-blind, placebo-controlled, phase 2a PORTOLA study and open-label extension},
  author = {Craig S. Lammert and Ethan M. Weinberg and Seth N. Sclair and Robert J. Fontana and Neel K. Anand and Janet L. Anderl and David Bade and Shraddha Desai and Christopher J. Kirk and Diana Lam and Eric Lowe and Tony Muchamuel and Kiruthi Palaniswamy and Rachel Peterson and Kathryn Ray and Zung To and Brian B. Tuch and Jennifer A. Whang and Aparna Goel and Unknown},
  year = {2026},
  journal = {Hepatology},
  doi = {10.1097/hep.0000000000001840},
  url = {https://doi.org/10.1097/hep.0000000000001840}
}

RIS

TY  - JOUR
TI  - Safety and efficacy of zetomipzomib in relapsed or insufficiently responding autoimmune hepatitis: Results from the randomized, double-blind, placebo-controlled, phase 2a PORTOLA study and open-label extension
AU  - Craig S. Lammert
AU  - Ethan M. Weinberg
AU  - Seth N. Sclair
AU  - Robert J. Fontana
AU  - Neel K. Anand
AU  - Janet L. Anderl
AU  - David Bade
AU  - Shraddha Desai
AU  - Christopher J. Kirk
AU  - Diana Lam
AU  - Eric Lowe
AU  - Tony Muchamuel
AU  - Kiruthi Palaniswamy
AU  - Rachel Peterson
AU  - Kathryn Ray
AU  - Zung To
AU  - Brian B. Tuch
AU  - Jennifer A. Whang
AU  - Aparna Goel
AU  - Unknown
PY  - 2026
JO  - Hepatology
DO  - 10.1097/hep.0000000000001840
UR  - https://doi.org/10.1097/hep.0000000000001840
ER  -

APA

Lammert, C. S., Weinberg, E. M., Sclair, S. N., Fontana, R. J., Anand, N. K., Anderl, J. L., Bade, D., Desai, S., Kirk, C. J., Lam, D., Lowe, E., Muchamuel, T., Palaniswamy, K., Peterson, R., Ray, K., To, Z., Tuch, B. B., Whang, J. A., Goel, A., & Unknown (2026). Safety and efficacy of zetomipzomib in relapsed or insufficiently responding autoimmune hepatitis: Results from the randomized, double-blind, placebo-controlled, phase 2a PORTOLA study and open-label extension. Hepatology. https://doi.org/10.1097/hep.0000000000001840

Source records

crossref · retrieved 2026-09-26T11:53:54.284Z